Macroaxis: Personalized Investing
Simple Personalized Investing

S&P 500   1,667   17.00  Index Moved Up 1.03%
FNMFO FNMFO 096770 KDDIF Junk Bonds Macroaxis 15 Raw Materials 
United States  USA  |  Investing Opportunities


Processing
Collecting data for WPI

Watson quote and profile

 
 Companies |  Insiders  | Dashboard  
     
125.5
  
STOCK
0.00  No Change   0.00%  
May 18 2013 

Diversification Suggestion

Use Watson to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment
Analyze Watson Pharmaceuticals Trend or Check current 30 days Watson correlation with market (S&P 500)
1 Month Beta 1.29  
Highest Price:  
Lowest Price:  
125.5  
96.68  
May 17 2013 
April 18 2013 
As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Watson will likely underperform.
Watson Pharmaceuticals Inc Large BetaWatson Pharmaceuticals Beta Legend
WPI United States NYSE
Watson Pharmaceuticals Inc
http://www.watson.com
Contact Number: 862. 261. 7000
Traded on New York Stock Exchange
    
Current Valuation11.79 B
Shares Outstanding127.76 M
Number of Shares Shorted2.83 M
Revenue5.71 B
 United States Russel   1.11 % Macroaxis: change 1.11 Moved Up  
 
 United States SP 500   1.03 % Macroaxis: change 1.03 Moved Up  
 
 United States NYSE   0.92 % Macroaxis: 0.92 Moved Up  
 
 United States Nasdaq   0.69 % Macroaxis: 0.69 Moved Up  
 
 thisGreen WPI WPI agains markets  0.00 % No Change  
Compare to Competition Get Alpha   Get Advice

Watson Leadership

Kenneth Gatchalian President CEO, COO, Director
Paul Bisaro CEO and President and Director
Graham Marshall Non-Executive Independent Chairman of the Board
Renato Magadia Chairman of the Board, CEO, CPA

Watson Price and Market Media

The median price of Watson for the period between Thu, Apr 18, 2013 and Sat, May 18, 2013 is 106.49 with a coefficient of variation of 8.9. The daily time series for the period is distributed with a sample standard deviation of 9.64, arithmetic mean of 108.28, and mean deviation of 7.76. The Stock received substential amount of media coverage during this period.
Watson         Market
Price Growth (%)
 
1
Federal Trade Commission v. Actavis Inc A quick look into re...04/23/2013Macroaxis: News
2
Shire Ends Patent War With Actavis Watson Over ADHD Drug04/26/2013Macroaxis: News
3
Actavis Completes Purchase of Serbia Zdravlje for 9.2 Millio...04/30/2013Macroaxis: Bloomberg News
4
Earnings Preview Monster Worldwide Nu Skin OchZiff Shell Act...05/02/2013Macroaxis: News
5
ACTAVIS INC Actavis Inc. to Present at the Bank of America M...05/08/2013Macroaxis: News
6
Actavi NDA for ProgestinOnly Patch Accepted for Filing by FD...05/14/2013Macroaxis: News
7
Novartis Considers Possible Bid for Actavis05/16/2013Macroaxis: News

Watson Summary

Watson Pharmaceuticals Inc [WPI] is traded on New York Stock Exchange in USA. It is located in Watson Pharmaceuticals, Inc.Parsippany, NJ and employs 6,686 people. The company currently falls under 'Large-Cap' category with total capitalization of 10.92 B. Watson Pharmaceuticals Inc has 127.76 M outstanding shares of which 2.83 M shares are at this time shorted by investors with about 3.1 days to cover shorted positions.
Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical solutions in the United States, western Europe, Canada, Australasia, Asia, South America, and South Africa. more
Past Market
Over 30
Days
23
Out Of
100
 
Chance of
Less
Than
12 %
 
Follow Watson with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Watson to your reader
 

Watson Research Report

Watson vs. Federal

Correlation analysis and fundamentals comparison between Watson Pharmaceuticals and Federal National Mor

Watson Executives

Todd Joyce CFO -Global

Watson Directors

Albert Hummel Independent Director
Fred Weiss Independent Director
Mathew Walker Executive Director
Ruben Torres Independent Director, MBA
Teck Wong Director

Watson Fundamentals

Current Valuation vs Current Asset
Return On Asset vs Current Liabilities
Current Valuation vs EBITDA
Price to Book vs Current Liabilities

Watson vs Competition

Watson vs. Federal National Mortgage Association
Watson vs. Federal National Mortgage Association
Watson vs. SK Innovation
Watson vs. KDDI Corp
Watson vs. Japan Tobacco Inc
Watson vs. Inpex Corporation
Watson vs. AP M
Watson vs. AP M
Watson vs. Citigroup Inc
Watson vs. Akbank TAS

Watson May 18 2013 Opportunity Range

Downside Deviation0.7085
Information Ratio0.3144
Maximum Drawdown12.44
Value At Risk(0.64)
Potential Upside4.6

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium